Chimeric antigen receptor T cell therapeutics - Shanghai Unicar-Therapy Bio-medicine Technology

Drug Profile

Chimeric antigen receptor T cell therapeutics - Shanghai Unicar-Therapy Bio-medicine Technology

Alternative Names: CAR-T-Shanghai-Youkadi-Biomedical-Technology

Latest Information Update: 08 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shanghai Unicar-Therapy Bio-medicine Technology
  • Developer Shanghai Unicar-Therapy Bio-medicine Technology; Soochow University; The Third Xiangya Hospital of Central South University
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-Hodgkin's lymphoma
  • Phase I/II Lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase I Multiple myeloma; Pancreatic cancer; Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 01 Jan 2018 Phase-I/II clinical trials in Lymphoma (Recurrent, Second-line therapy or greater) in China (Infusion) (NCT03468153)
  • 09 Dec 2017 Efficacy and adverse events data from a phase I trial in Multiple myeloma presented at the 59th Annual Meeting and Exposition of the American Society of Haematology (ASH-2017)
  • 12 Sep 2017 Shanghai Unicar-Therapy Bio-medicine Technology plans a phase I/II trial for Precursor-cell-lymphoblastic-leukaemia-lymphoma (Refractory metastatic disease, In children, In adolescents, In adults) (NCT03275493)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top